MDGL
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Article Summary
HOLD- Madrigal Pharmaceuticals Inc. (NASDAQ: MDGL) announced that it granted equity awards on July 15, 2026 to ten new non-executive employees as equity inducement awards under the terms of Madrigal's 2025 Inducement Plan under Nasdaq Listing Rule 5635(c)(4), with the equity awards granted as inducement material to employees' acceptance of employment with Madrigal Pharmaceuticals.
- The biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) received options to purchase 4,770 shares of common stock, 7,433 time-based restricted stock units, and 1,908 performance-based units, with options having exercise price of $550.25 per share equal to closing price of company's common stock on grant date, with 25% of option shares vesting on first anniversary of grant date and 6.25% on each quarterly anniversary following grant date.
- The new employees received options in aggregate, in aggregate.
Free users see 3 BUY signals per day. Premium unlocks all of them, plus instant email alerts.
See Plans
Growth Stock Scoring Breakdown
| METRIC | VALUE | WEIGHT | ANALYSIS |
|---|---|---|---|
| Sales Growth TTM ? | 256.8% | 25% | 100.0 ptsExceptional (256.8%) - Hypergrowth |
| EPS Growth Next 5Y ? | 0.0% | 25% | 10.0 ptsVery Weak (0.0%) - Minimal expectations |
| Target Price Upside ? | 24.2% | 20% | 70.0 ptsGood Upside (24.2%) - Target: $678.93 vs Current: $546.79 |
| Gross Margin % ? | 92.9% | 15% | 100.0 ptsExceptional (92.9%) - Strong pricing power |
| Drawdown from 52-Wk High ? | -11.1% | 15% | 40.0 ptsMild Pullback (-11.1%) - Light entry opportunity |
Disclaimer: This rating is for informational purposes only and is not financial advice.
All data sourced from Finviz.
Always conduct your own research and consult with a financial advisor before making investment decisions.
Past performance does not guarantee future results.
About MDGL
- Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
- It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
- The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.